tiprankstipranks

Cabaletta Bio initiated with a Buy at Citi

Citi initiated coverage of Cabaletta Bio with a Buy rating and $22 price target. The analyst acknowledges the “increasingly crowded” competitive landscape for autologous CD19-directed CARTs, but likes Cabaletta’s “de-risked” development strategy for lead asset CABA-201, which was designed specifically for the treatment of autoimmune disorders with a fully human CD19 binder and a 4-1BB costimulatory domain. Citi sees CABA-201 as a potential multi-billion-dollar product across lead indications systemic lupus erythematosus and myositis.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on CABA:

Disclaimer & DisclosureReport an Issue